Israel Englander’s Ascendis Pharma A/S ASND Stock Holding History

Israel Englander’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$347K	Buy	+1,300	New	+$304K	﹤0.01%	5040
2025 Q4	–	Sell	-20,000	Closed	-$3.98M	–	5994
2025 Q3	$3.98M	Buy	+20,000	New	+$3.73M	﹤0.01%	3368
2025 Q2	–	Sell	-10,000	Closed	-$1.56M	–	5839
2025 Q1	$1.56M	Buy	+10,000	New	+$1.43M	﹤0.01%	4007
2024 Q4	–	Sell	-38,000	Closed	-$5.67M	–	5941
2024 Q3	$5.67M	Buy	+38,000	New	+$5.13M	﹤0.01%	2723

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Israel Englander's ASND Position: Q2 2026 in Review

Israel Englander increased its Ascendis Pharma A/S (ASND) stake by 41% in Q2 2026, buying an estimated $18.1M and bringing the position to 266,708 shares worth $71.1M. The position accounts for 0.03% of the portfolio, ranked #691.

Israel Englander first reported a position in ASND in Q1 2015 and has held it in 40 quarters since. The position peaked at $162M in Q1 2019. 310 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Israel Englander held 266,708 shares of Ascendis Pharma A/S worth $71.1M as of Q2 2026.
Israel Englander bought 77,681 Ascendis Pharma A/S shares in Q2 2026, an estimated $18.1M.
Ascendis Pharma A/S made up 0.03% of Israel Englander's portfolio in Q2 2026, its #691 holding.
Israel Englander first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 40 quarters since.
Israel Englander's Ascendis Pharma A/S position peaked at $162M in Q1 2019.
310 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.